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potential differences which should be considered when selecting data to answer 
specific research questions.
PRM43
Real woRld ReseaRch in latin aMeRica: oPPoRtunities, souRces and 
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Objectives: Real world evidence (RWE) is critical for the assessment of health 
technologies. This study was conducted to define and compare the governance 
of, and data sources available for, real world research (RWR) in Latin America (LA) 
and Canada. MethOds: Systematic literature review was conducted to exam-
ine administrative and clinical data for 10 major countries ranked by population. 
Research terms were defined by an international team, and reports were reviewed 
and assessed for content, quality and bias by two investigators. Data was sum-
marized in major and minor domains for each country. Results: Governance of 
RWR differed between countries, both from a regulatory and an ethics committee 
review perspective. Regulatory review was required for non-interventional studies 
in 4/10 countries. Ethics review varied importantly in complexity, site (local, cen-
tral) and duration (which could exceed 1 year). Administrative and clinical search 
terms returned over 1800 reports from LA, principally from Brazil, Mexico, Argentina 
and Chile, of which over 700 contained contributory information on data sources 
for RWE. Of these, 156 addressed international registries or databases including 
countries in LA, 245 reported national registries or databases within one country in 
LA, and 308 reported registries or databases from a single or multiple institutions 
within a country. Principal administrative categories included claims, prescription 
and economic data sources, while principal clinical categories included data sources 
relating to cancer, cardiology, neurology, respirology, and diabetes. In contrast, a 
total of over 2000 reports were obtained for Canada alone, with a similar categorical 
distribution to that observed in LA. cOnclusiOns: Latin America is a region with 
diverse health systems, inputs and outcomes. While sources for RWE exist in sev-
eral larger countries, comprehensive national or regional databases are uncommon 
compared with a mature public health care system such as Canada. Improvement 
of database quality and well-designed prospective population studies are critical 
to enhance the RWE base.
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bAckgROund: Real-world data are required to fully assess the value of treatments 
in clinical practice. Given the importance of having all available data to make this 
assessment, while ensuring efficiencies in preventing duplication of data collection, 
the absence of a central repository of longitudinal data sources on cancer patients 
in Europe remains a challenge. Objectives: i)Identify and characterize existing 
traditional and non-traditional data sources on lung cancer and renal cell carcinoma 
(RCC) patients in Europe; ii)Determine the utility of each identified data source 
for real-world research. MethOds: A systematic literature search was conducted 
using MEDLINE and Embase(01/01/06-20/12/13). MeSH and Emtree terms included 
the following concepts: lung cancer (small-cell and non-small-cell), RCC, real-world 
data (registry, cohort, etc), and European countries. Clinical trials, case reports, case 
series, literature reviews were excluded. Identified abstracts were screened and 
reviewed based on relevance to key concepts. For each data source, utility was 
assessed using the following variables: country, setting, type (e.g. registry, EMR, 
etc.), clinical and baseline characteristics, tumor, biomarkers, test results, treat-
ments, clinical and patient reported outcomes, resource utilization. Results: The 
search yielded 2,478 abstracts for lung cancer and 698 for RCC. Following screening, 
192(7.7%) and 102 (14.6%) were retained respectively. Data sources for lung cancer 
were equally distributed between general cancer and tumor specific registries. Most 
originated from the UK (33.3%) or France (13.8%). RCC data sources were primarily 
tumor specific and local with population size ranging from 56-1800. Data sources 
originated from Italy (22.5%), France, UK, and Germany (each 16.7%). Gap analyses 
with respect to the availability of specific data elements and utility for outcomes 
research will be presented. cOnclusiOns: Data sources on cancer are highly frag-
mented in Europe, especially for RCC, emphasizing the need for database mapping. 
Completeness and consistency of the data elements needed to support technology 
assessments are variable.
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Objectives: To establish quality of care benchmark estimates (HEDIS, PQA, or NQF) 
for Asthma, COPD, and Diabetes in the US Commercial Employer Sponsored Health 
Insured Population (EIS) for 2011. MethOds: The Marketscan Commercial claims 
database from 2010-2011 was used to identify the EIS population during 2011 and 
those patients with Asthma, COPD, and Diabetes. Patients needed at least 6 months 
of continuous coverage during 2011 and coverage during December 2011. Asthma, 
COPD, or Diabetes must have been recorded during 2011 or in the 6 months prior and 
was identified using a clinically approved coding algorithm. A weight was assigned 
Objectives: Capturing dosing of biologic and non-biologic Disease Modifying Anti-
Rheumatic Drugs (DMARDs) using electronic medical records is challenging. Precise 
estimates of weekly dose using structured pharmacy data alone are difficult since 
quantity dispensed is not standardized for injectable products. Natural Language 
Processing (NLP) software was developed to extract elements of the prescribing 
provider’s medication instructions (SIGs) to compute the average weekly dose. The 
objective was to evaluate the accuracy of the NLP software’s computation of the 
average weekly dose by medication and route. MethOds: The NLP software com-
puted the average weekly dose for biologic and non-biologic DMARDs and was 
evaluated against the annotator-derived reference standard. Using an annotation 
guideline, trained annotators annotated relevant information from SIGs including 
unit strength, dose per administration event and the schedule of administration 
events. The NLP software was then trained on 11,937 records. A validated set of the 
annotator-derived reference standard that contained 140 SIGs per medication and 
route was used to evaluate the NLP accuracy and compute the 95% Confidence 
Interval (CI) of accuracy. Results: The overall accuracy for injectable biologic and 
oral and injectable non-biologic DMARDs was 89.1% (95% CI: 87.9%-90.3%). Accuracy 
was 95.3% (95% CI: 91.9%-98.7%) for oral methotrexate, 84.7% (95% CI: 78.9%-90.5%) 
for injectable methotrexate, 87.9% (95% CI: 82.5%-93.3%) for sulfasalazine, and 92.9% 
(95% CI: 88.7%-97.2%) for hydroxychloroquine. For biologics, accuracy was 92.1% 
(95% CI: 87.6%-96.6%) for etanercept, 98.6% (95% CI: 96.7%-100%) for adalimumab 
and injectable abatacept 90.0% (95% CI: 85.2%-94.8%). The lower bound of the 95% CI 
ranged from 79.1%-100% for biologic DMARDs and from 78.9%-91.9% for non-biologic 
DMARDs. cOnclusiOns: The lower bounds of the 95% CI for most medications 
were greater than 80%. These results indicate that the NLP software can be used to 
extract information to calculate the weekly dose of DMARDs from narrative medi-
cation schedules.
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Objectives: Private claims databases have been a rich source of information related 
to health care delivery, though the fragmented nature of U.S. health insurance 
market limits their ability to provide a comprehensive view of a given geography. 
Additionally, claims data are often expensive (> $25,000) - restricting access to those 
with the economic means to afford it. To provide a more thorough view of health 
costs and practice at the state level, 11 states have created all payer claims databases 
(APCDs). An analysis was conducted to review their designs and consider how they 
will impact health economic analyses and health services research. MethOds: 
A detailed review of 11 APCDs was conducted using a combination of secondary 
research and key informant interviews. This included reviewing the legislation that 
mandated and funded their creation, the rules under which they operate, and the 
data they collect and make available. The multi-state analysis was then informed 
by a deeper analysis of the data integration opportunities, reporting abilities, and 
costs for data exchange for Maine’s newly revised APCD. Results: Across states, 
APCDs make publicly available a wide array of health data in a manner that ensures 
privacy and security of personal health information. Each APCD provides varying 
levels of granularity in health care resource utilization, demographic comparisons, 
expenditures, and quality/safety data. Ability to customize data pulls is growing, 
though private claims datasets appear to have greater flexibility. In Maine’s APCD, 
commercial and Medicaid medical, pharmacy, and dental data are available to 
researchers, with quarterly block releases and opportunities for individual que-
ries. cOnclusiOns: APCDs are providing researchers with an open-access, afford-
able pathway to understand health care resource utilization and practice across 
entire populations. As more come online, greater participation in health economic 
and health services research can be expected.
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Objectives: Lung cancer (LC) leads cancer-related mortality in the U.S.; often 
diagnosed at an advanced stage with poor prognosis. Non-small cell lung cancer 
(NSCLC) accounts for approximately 85% of all LC. Real-world research in NSCLC 
necessitates clinical and longitudinal detail typically unavailable from any single 
retrospective data source. This study describes and benchmarks a comprehensive 
disease record for NSCLC patients created by linking the PharMetrics Plus (PMTX) 
database to an oncology electronic medical records (OEMR) database. MethOds: 
Adult NSCLC patients (ICD-9-CM code 162.2 to 162.9) with either confirmed histol-
ogy, use of pemetrexed, or without evidence of etoposide use were identified from 
PMTX and OEMR databases between 1/1/2006 and 7/31/2013. Patients were linked 
using a HIPAA-compliant encryption algorithm. Key patient characteristics from the 
linked sample were compared with the National Cancer Institute SEER registries 
NSCLC population (2006-2010, n= 152,465). Results: 182,425 NSCLC patients were 
identified (PMTX:156,029; OEMR:26,906), with 510 patients linked to both databases. 
Among linked patients, 50% were female, 36% were considered non-squamous (con-
firmed by histology or use of pemetrexed) and 47% were metastatic at diagnosis. 
Treatment data (surgical resection, radiation, or chemo/biological therapy) were 
available for 97% of the linked patients; 64% with platinum and 30% with pem-
etrexed therapy. The SEER population had a higher proportion of patients > = 65 
years at diagnosis (64% vs. 25%) but a lower portion (21%) metastatic at diagnosis 
compared to the linked sample. cOnclusiOns: This study demonstrates that data-
bases can be linked to provide a longitudinal, clinically rich view of an NSCLC popu-
lation. Comparisons between the linked sample and the SEER population highlight 
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and accessing the best available evidence to address a given research question. Our 
objective was to develop a systematic methodology to identify observational data 
sources for specific needs and to test it in both common and rare conditions in a 
range of therapeutic areas. MethOds: Systematic literature and Web searches, 
supplemented with email and telephone contact with data owners, were used to 
identify and characterize data sources suitable for use in 6 observational research 
programs spanning oncology, cardiology, and respiratory medicine. Data were cap-
tured and project-specific evaluation criteria applied regarding: study population; 
target geographies; type of clinical, diagnostic, and health care data required; length 
of follow up; and ability to identify patients across data sources. Data sources best 
meeting program objectives were recommended. Results: Over 14,000 references 
were screened across 6 separate studies. Of these, 4.5% to 8.6% were relevant to each 
study and were reviewed further. Direct contact with data owners was often needed 
to clarify whether inpatient and outpatient drug utilization, laboratory and imaging 
results, clinical assessments, health care utilization, patient-reported outcomes, 
and mortality data were available. Detailed characterization of the data sources 
identified by the systematic search reduced their number by 150–300-fold. This 
generated a manageable number of data sources (4–17 per study) to address specific 
research questions, including for prevalent cardiac conditions as well as a rare 
respiratory sub-population, in target geographies. cOnclusiOns: The approach 
was effective in identifying accessible, relevant, and high-quality data for both rare 
and more prevalent conditions. A systematic understanding of real-world evidence 
has helped to guide observational research programs in diverse therapeutic areas 
with specialized data requirements.
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Objectives: With the explosion of medical data, it is necessary to develop software 
tools to support the process of evidence review and synthesis that is fundamental to 
Evidence-Based Medicine. Furthermore, as predictive models are being increasingly 
integrated into clinical decision making for individual patients, there is an even 
greater need for a practical tool that enables development, validation, and uncer-
tainty quantification of models in a robust, automatic and efficient way. MethOds: 
We developed Evidence Synthesis Engine (ESE), a software platform that enables 
users to display, compare and synthesize evidence from multiple data sources, to 
estimate disease risks, to validate risk models, to build predictive models, to rec-
alibrate existing models as new data becomes available, to evaluate improvement 
in prediction performance between two models, and to quantify the accuracy of 
a predictive model in different subpopulations. Results: We applied ESE to data 
from eight cardiovascular studies (six cohort studies and two clinical trials) with 
a total size of over 147,000 participants. ESE allows users to create customized 
pooled cohorts and subpopulations from these data sources. Users can assess the 
performance of predictive models for different subpopulations in real time. Several 
metrics were used for model evaluation: cumulative incidence, calibration plots, 
receiver operating curve and net reclassification index. ESE also allows users to 
generate and then assess models for risks of MI, stroke, heart failure, coronary 
death or composite cardiovascular outcome for a predefined subpopulation from 
selected datasets. We used ESE to evaluate the performance of five cardiovascular 
risk equations. The results suggested that compared to four other well-accepted 
cardiovascular risk equations, the 2013 Pooled Cohort Equations for 10-year risk of 
ASCVD could have superior performance for the individuals considered in these 
eight studies. cOnclusiOns: ESE proves to be a useful tool for advancing the devel-
opment and application of predictive modeling in medicine.
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Objectives: The abundance and availability of health care data has risen expo-
nentially in recent time, coming from a variety of health systems. These data have 
the ability to provide rich insight into the outcomes of care, standards of care and 
specifically the descriptive patterns of treatments. However the barrier to this rich 
insight is twofold; technical and methodological. This methods piece will demon-
strate how the application of high performance computing technology has been 
able to erode technical and methodological boundaries to these data and provide 
fresh insight in to the chronic disease management within longitudinal patient 
records. MethOds: Data from MarketScan, Clinical Practice Research Database 
(CPRD), IMS-Health and the Hospital Episodes Statistics (HSCIC) have been loaded 
into a High performance computing centre, hosting > 100 Million patient lives with 
> 15 years of linked longitudinal data. Algorithms to define treatment & diagnostic 
exposures/duration and procedural observations, defined with specific structure 
query languages. These views feed a visual analytics interface of prevalence/inci-
dence/demographic breakdown/patient interactions and specifically patient path-
ways. Results: The combination of standardised visual analytics interfaces on 
these health care data highlight nuances and intricacies in longitudinal patient 
pathways and records. These automated technologies enable the researchers to 
instantaneously assess and triangulate trends of disease presentation, treatment 
and laboratory assessments. We highlight the use of these tools to assess factors 
used in a Bayesian modelling exercise to assess fluctuations of a laboratory result 
recorded over time on the prediction of a rare event. cOnclusiOns: Generation and 
analytics of disease cohorts and from high dimensional datasets requires careful 
longitudinal interrogation of factors prior to analysis. This factor analysis is often 
missed in the creation of disease segments and often leads to misinterpretation of 
data. The use of visual analytics tools combined with high performance comput-
to each patient using the Marketscan National Weights for 2011. Estimates of the ESI 
population were calculated by summing the weights across the study population. 
The same approach was used for patients with a condition or measure of interest. 
A modified “precision rounding” approach was applied to subpopulation estimates 
to ensure that the sum each sub-category estimate would add to the total popula-
tion. Results: We estimated a total population of 160,714,971 with EIS in 2011. Of 
those, 0.7% had COPD, 2.4% had Asthma, and 5% had Diabetes. A total of 5.9% of 
COPD patients had a level 2 or 3 exacerbation and 31.4% of newly diagnosed patients 
received spirometry testing. For Asthma patients, 13.6% had 2+ oral steroid fills, and 
2.5% had 4+ SABA fills within a period of 90 days. For Diabetes patients 50% had 
2+ HbA1c tests, 25% had an eye exam, and 70.4% had an LDL test. cOnclusiOns: 
With the burden of chronic diseases remaining a significant source of health care 
costs, the ability to estimate national prevalence and projection estimates obtained 
from claims data provide an excellent source of information to benchmark quality 
of care in the hope of improving quality of life for patients.
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Objectives: Created in 2002, the Patient-Reported Outcome and Quality of Life 
Instruments database (PROQOLID) provides a detailed description of 773 generic, 
disease-, and population-specific Patient-Centered Outcomes measures on the 
Internet (www.proqolid.org). The objective of this study was to find out if PROQOLID 
could help researchers identify questionnaires available in French for use in 
Quebec. MethOds: The PROQOLID database was explored on November 10, 2013 
using the search engine and selecting in the language field the key words “French 
for Canada.” Results: Two hundred and twelve questionnaires were identified 
representing 27.42% of the instruments available in PROQOLID [in comparison, 383 
questionnaires (49.54%) were available in French for France]. Out of these 212 ques-
tionnaires, 26 were generic. Twenty different therapeutic areas were identified (e.g., 
endocrine system diseases, neoplasms, nervous system diseases, respiratory tract 
diseases, or psychiatric disorders), representing 75 different indications, and 83.33% 
of the therapeutic areas included in PROQOLID (n= 24). Twenty-three questionnaires 
were available for pediatric use (children and/or adolescents), either generic [e.g., 
Pediatric Quality of Life Inventory Generic Core (PedsQL)], or disease-specific [e.g., 
Paediatric Asthma Quality of Life Questionnaire (PAQLQ)]. Asthma and diabetes 
mellitus were the most frequent indications (16 questionnaires available for each 
indication), followed by dementia (including Alzheimer’s disease) and dyspepsia 
(eight questionnaires for each indication), pain (seven questionnaires), and sleep 
disorders (six questionnaires). Within the therapeutic area of neoplasms, five differ-
ent indications were identified (brain, breast, lung, myeloma and ovary), and seven 
questionnaires for generic use [e.g., EORTC Quality of Life Questionnaire – Core 
Questionnaire (EORTC QLQ-C30), Functional Living Index – Cancer (FLIC)]. Not a 
single instrument was identified in therapeutic areas such as bacterial infections 
and mycoses; congenital, hereditary diseases; stomatognathic diseases; and surgical 
procedures. cOnclusiOns: This overview showed that Patient-Centered Outcome 
measures available for use in Quebec cover a wide variety of indications.
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Objectives: Monitoring patient care outcomes is essential to ensure quality of 
care, hospital performance assessment and identification of areas of deficiency and 
for evaluation of strategies designed to overcome those weaknesses. We aimed to 
assess the impact of clinical database development on quality of care in the area of 
Paediatrics and Congenital Cardiac Surgery. MethOds: The Cardiothoracic surgery 
division at the Aga Khan University Hospital maintains a computerized database 
of all the patients undergoing cardiac surgery since July 2006. For this study, data 
of 1236 patients operated between July 2006 and Sep 2013 was analyzed. Major 
measures of outcomes included in-hospital and 30 day mortality and morbidity 
outcomes like reopening, sepsis prolong ventilation, arrhythmias low cardiac output 
syndrome. Results: Out of a total of 1236 heart surgeries, the most common open 
heart surgeries were VSD 27%, TOF 24% were, and 13% were ASD. In closed heart 51% 
were Modified BT shunts, 17% were PDA. The overall 30-day mortality in open heart 
was 7.0%, and in closed heart it was 7.3%. Post-surgery more common complication 
in open heart surgery was prolong ventilation which was 39%,arrhythmias 14%,reo-
penings 11% and sepsis 5%total morbidity was 29% while in closed heart most com-
mon complication was prolong ventilation which was 31%, total morbidity was 21%. 
Readmissions after 30 day of Discharge were 8.4% mainly for respiratory infection. 
Followed with 85% patients were alive, 0.6% were died at 30 day patients follow up 
changes TOF;early extubation and improving survival. VSD: on table extubation or 
extubation with 4 hours – minimal morbidity and early discharges. ASD: on table 
extubation. cOnclusiOns: Updated and stringently maintained database helped 
to identify deficiencies, strength and trends at our hospital and also to design strate-
gies for continuing improvement in patient care. Also provides scientific evidence 
for comparing results with other institutions of the region and world.
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Objectives: Real-world evidence informs product development, pricing, and reim-
bursement as well as patient care. An ongoing challenge, however, is in identifying 
